Gonadotropin-releasing hormone agonists, often called GnRH agonists, are medications that alter signaling between the brain, pituitary gland, and reproductive organs. In breast cancer care, they may be used to suppress ovarian function in patients whose tumors are sensitive to estrogen, particularly before natural menopause. These drugs are administered by injection and may require recurring visits to a clinic, where trained personnel prepare and deliver the medication. Although each appointment may be relatively brief, the cumulative burden can be substantial when patients must arrange transportation, take time away from work or caregiving, wait for treatment, and return home afterward. For patients already undergoing surgery, chemotherapy, radiation, endocrine therapy, or frequent monitoring, repeated injection visits can add another layer of logistical strain.

The home-based model studied by Erin M. Bange, MD, MSCE, and colleagues combined patient self-administration or home administration with telemedicine guidance. Rather than eliminating clinical oversight, the model moved selected parts of the process into the patient’s living environment while preserving access to professional instruction and follow-up. Telemedicine can be used to explain the medication schedule, review injection technique, assess whether a patient is comfortable handling the device or medication, and address questions about side effects. This type of hybrid care is technically different from simply mailing a prescription to a patient: it requires coordination among clinicians, pharmacies, insurers, and patients, as well as systems for confirming that the drug is obtained, stored, prepared, and administered correctly.

The study’s central outcome was not only whether patients could complete an injection at home, but whether the arrangement improved the experience of treatment. Participants described convenience and time savings as major advantages. A home injection may eliminate travel to an oncology center and reduce the hours spent navigating appointments, registration, clinical preparation, and post-treatment discharge. For people living far from cancer centers, those benefits may be especially meaningful. The model may also help patients maintain employment, manage family responsibilities, and avoid the physical and emotional disruption associated with repeated medical visits. In cancer care, these practical factors are not merely matters of comfort; they can affect how patients perceive treatment, engage with care teams, and sustain long-term therapy.

Most patients who completed the pilot chose to continue home injections after the initial evaluation. That decision provides an important signal about acceptability because it reflects a preference made after patients had experienced the process rather than a hypothetical opinion gathered before treatment. Continued participation may indicate that patients found the training adequate, the technology usable, and the remote clinical support responsive to their needs. It also suggests that home administration can be integrated into ongoing care for at least some individuals receiving injectable hormonal therapy. However, the decision to continue should not be interpreted as proof that the model is appropriate for everyone. Patients differ in health literacy, dexterity, vision, anxiety about needles, home circumstances, language needs, and access to reliable internet or private space for telemedicine visits.

The technical and clinical safeguards surrounding home injection are therefore essential. A successful program must establish that the patient understands the dosing schedule and can identify when assistance is needed. Medication storage requirements, preparation steps, injection-site selection, needle disposal, and management of local reactions must be explained clearly. Patients also need instructions for recognizing symptoms that warrant urgent medical attention, although many injection-related concerns may be handled through scheduled or on-demand telemedicine contact. Clinicians may need to document training, verify administration, monitor adherence, and provide a pathway for in-person evaluation when remote assessment is insufficient. These requirements illustrate why the study’s model is best understood as telemedicine-enabled oncology care rather than a simple transfer of responsibility from professionals to patients.

The investigators also identified obstacles that could prevent widespread adoption. Insurance denials and higher copayments for at-home administration may make the home option more expensive than receiving the same therapy in a clinic. This creates a paradox in which a treatment pathway that saves patients time may increase their direct financial burden. Coverage policies can be complicated because the medication, injection service, pharmacy dispensing, telemedicine support, and home administration may be classified under different benefit structures. A patient may therefore face different costs depending on where the drug is obtained and who administers it. Without payment models that recognize the value of remote clinical support and the patient’s time, home-based care could remain available mainly to those with favorable insurance, flexible schedules, stable internet access, or the resources to absorb unexpected expenses.

The findings arrive as oncology practices continue to test which elements of cancer care can be delivered safely beyond hospital and clinic walls. Remote monitoring, virtual consultations, specialty pharmacy services, and patient-directed treatment are expanding, but each approach must be evaluated according to the medication involved and the risks associated with missed or incorrect doses. GnRH agonist therapy presents a useful setting for this work because it is administered intermittently and follows a predictable treatment plan, yet it remains part of a complex cancer regimen requiring clinical coordination. The home model could potentially reduce congestion in infusion and injection clinics, allowing staff time to be redirected toward patients who need hands-on care. Any such operational benefit, however, should be considered alongside the need to preserve equity and avoid shifting hidden work onto patients or family members.

The study does not establish that every breast cancer patient should receive GnRH agonist injections at home, nor does it remove the need for individualized medical judgment. Instead, it provides evidence that a carefully supported option can reduce treatment burden and earn strong patient acceptance among those able to complete the pilot. Future research will need to clarify which patient characteristics predict successful home administration, how training should be delivered, whether virtual support remains effective over longer periods, and how home treatment affects adherence, safety events, quality of life, and total costs. Larger evaluations may also determine whether the model works across different health systems and communities, including patients with limited digital access or greater medical complexity.

For now, the results point toward a broader principle in cancer care: convenience can be a clinically relevant outcome when treatment extends over months or years. Moving an injection from the clinic to the home does not change the underlying biology of hormone suppression, but it can change the daily reality of receiving therapy. The challenge is to ensure that such flexibility is supported by reliable education, responsive telemedicine, appropriate clinical oversight, and insurance coverage that does not penalize patients for choosing home care. If those conditions are met, telemedicine-supported injection programs could become a practical way to make long-term breast cancer treatment less disruptive while preserving the safety and continuity of specialist care.

Subject of Research: Telemedicine-supported home administration of injectable gonadotropin-releasing hormone agonist therapy for patients with breast cancer.

Web References: https://jamanetwork.com/channels/womens-health

References: Bange EM et al. JAMA Network Open. doi:10.1001/jamanetworkopen.2026.29406

Keywords: breast cancer, gonadotropin-releasing hormone agonists, GnRH agonists, telemedicine, home injection, oncology care, hormone therapy, health care delivery, home care, patient convenience, treatment burden, insurance coverage, cancer treatment.

The PALOMA-2 trial, particularly its fully enrolled Cohort 5, evaluated the efficacy and safety of the Q4W (every four weeks) subcutaneous amivantamab in combination with lazertinib as a frontline therapeutic strategy for treatment-naïve patients diagnosed with EGFR Ex19del or L858R mutated advanced NSCLC. Amivantamab, a bispecific antibody targeting both EGFR and MET receptors, is designed to inhibit key proliferative and survival signaling pathways in tumor cells displaying these specific genetic alterations. Lazertinib, a potent third-generation EGFR tyrosine kinase inhibitor (TKI), complements this mechanism by selectively targeting mutant EGFR, thereby enhancing the therapeutic impact.

Among the 77 patients enrolled in the study, the median age was 63 years, reflecting a representative patient population, with demographic diversity including 68% female participants and 62% of Asian descent. Notably, 43% of patients presented with brain metastases at screening, emphasizing the real-world complexity and aggressiveness of EGFR mutation-positive NSCLC that necessitates effective systemic therapies capable of penetrating central nervous system compartments.

The dosing schedule analyzed in the trial revealed an impressive objective response rate (ORR) of 82% as assessed by investigators, which was corroborated by independent central review (ICR) confirming an ORR of 87%. These figures signify a substantial anti-cancer effect rarely matched in this heavily studied patient subgroup. Furthermore, the confirmed ORR remained high at 79% by investigator assessment and 83% by ICR. Median time to response was rapid as well, occurring at 8.1 weeks, highlighting the regimen’s ability to induce swift tumor regression.

Importantly, the median duration of response, progression-free survival (PFS), and overall survival metrics were not yet reached at the 6.5-month follow-up mark, suggesting durable benefits that warrant longer observation. The durability of response, coupled with high initial efficacy, reinforces the potential for this regimen to become a new standard of care option that balances therapeutic potency with quality of life considerations.

Safety data from the study underscore the regimen’s favorable tolerability profile. Administration-related reactions (ARRs), a common issue with antibody therapies, were observed in only 12% of participants, with a single Grade 3 or higher event reported, representing a notable reduction compared to prior intravenous or more frequent subcutaneous dosing methods. This reduction in high-grade ARRs signals an important step forward in minimizing treatment-related discomfort and adverse sequelae.

Common adverse events predominantly reflected the expected class effects of EGFR and MET pathway inhibition, including dermatologic manifestations such as paronychia and rash, as well as hypoalbuminemia. These toxicities were generally manageable and consistent with prior experience using these agents. Venous thromboembolic events (VTEs) appeared in 13% of patients but were limited to less severe grades, with no reports of Grade 3 or higher VTE complications, and bleeding events remained rare at a frequency of 1%, further cementing the regimen’s manageable safety profile.

Pharmacokinetic analysis revealed that mean plasma concentration levels of amivantamab with Q4W subcutaneous administration aligned closely with historical data from intravenous and every-two-week (Q2W) subcutaneous dosing schedules. This pharmacokinetic equivalence indicates that the prolonged dosing interval does not compromise drug exposure, adding mechanistic credence to the observed clinical efficacy and safety outcomes.

With just 8% of patients discontinuing therapy due to treatment-related adverse events, the Q4W administration regimen demonstrates not only clinical viability but also a meaningful enhancement of patient adherence potential—a critical factor in chronic cancer management. The subcutaneous route itself, compared to intravenous infusion, affords greater convenience for patients by reducing infusion chair time and associated resource utilization in outpatient oncology settings.

Dr. Susan Scott, leading investigator at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, emphasized that the trial’s data advocate for the incorporation of Q4W amivantamab dosing as a frontline strategy for EGFR-mutant NSCLC patients, underscoring that this less burdensome treatment model “offers a less burdensome treatment option without compromising efficacy.” According to her, the findings herald not only a therapeutic milestone but also a patient-centric evolution in lung cancer care, improving quality of life through simplified medication schedules.

This development is critically timely considering the ongoing global burden of lung cancer, as EGFR-driven NSCLC remains a prevalent and challenging disease entity with variable responses to targeted therapies. The flexibility and efficacy demonstrated by this subcutaneous Q4W dosing regimen open new horizons for therapeutic optimization and personalized cancer care paradigms.

The PALOMA-2 study’s positive outcomes resonate deeply within the research community, presenting an encouraging avenue for further exploration in subsequent phase trials and real-world clinical applications. The trial reinforces the growing consensus that targeted combinations leveraging antibody-based and kinase inhibitor modalities can deliver synergistic anticancer effects with manageable toxicity, a cornerstone principle in modern oncology innovation.

As the lung cancer field continues to evolve, the implications of these findings are profound: enabling effective control of tumor progression with improved patient experience may transform current treatment algorithms, particularly for the sizeable population of patients newly diagnosed with EGFR-mutant NSCLC, many of whom face rapidly advancing disease and complex clinical scenarios.

Looking ahead, longer-term follow-up and expanded patient cohorts will be essential to confirm the durability of response, overall survival benefits, and to further characterize the long-term safety profile of the Q4W amivantamab plus lazertinib combination. Still, the evidence amassed thus far provides a compelling rationale for healthcare providers to consider and advocate for subcutaneous amivantamab dosing strategies in future clinical practice guidelines.

In conclusion, the PALOMA-2 trial’s presentation at the 2025 WCLC stands as a landmark step forward in the quest to refine lung cancer therapeutics by integrating efficacy, convenience, and tolerability into new treatment paradigms that promise to improve outcomes for patients worldwide.

Subject of Research: Subcutaneous Amivantamab and Lazertinib Combination Therapy for Frontline Treatment of EGFR-Mutated Advanced Non-Small Cell Lung Cancer

Article Title: PALOMA-2 Trial Data Reveal Promising Efficacy and Safety of Once-Monthly Subcutaneous Amivantamab with Lazertinib in Untreated EGFR-Mutated NSCLC

News Publication Date: September 9, 2025

Web References: www.iaslc.org

Keywords: Lung cancer, NSCLC, EGFR mutation, amivantamab, lazertinib, targeted therapy, subcutaneous administration, PALOMA-2, clinical trial, EGFR Ex19del, L858R mutation, quality of life